# A Study of More Frequent Dosing of VCN-01 Combined With Standard Chemotherapy in Patients With Newly Diagnosed Metastatic Pancreatic Cancer

Source: https://onco.cc/trials/nct07701486/  
OnCo record `nct07701486` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Gemcitabine in pancreatic ductal adenocarcinoma, run by Theriva Biologics SL, now recruiting.

## Summary

A Study of More Frequent Dosing of VCN-01 Combined With Standard Chemotherapy in Patients With Newly Diagnosed Metastatic Pancreatic Cancer is a phase 1/2 interventional study registered as NCT07701486 by Theriva Biologics SL, with 6 participants planned, started 2026-08-03 and due to reach its primary completion in 2027-08-01. Interventions recorded: VCN-01 oncolytic adenovirus (zabilugene almadenorepvec) and Nab-paclitaxel + Gemcitabine.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07701486
- Phase: 1/2
- Setting: A Phase IIa, Single-arm, Single-center, Open Label, Proof-of-concept Trial Evaluating Increased Frequency Dosing of VCN-01 (Zabilugene Almadenorepvec) in Combination With Nab-Paclitaxel/Gemcitabine (GnP) in Patients With Newly-Diagnosed Metastatic Pancreatic Cancer
- Sponsor: Theriva Biologics SL
- Enrolled: 6

## Sources

- ClinicalTrials.gov NCT07701486: https://clinicaltrials.gov/study/NCT07701486

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- drugs: [Gemcitabine](https://onco.cc/drugs/gemcitabine/)

---
JSON: https://onco.cc/api/v1/entities/nct07701486.json